Question:
Our family has just ordered one of your Rife machines and are eagerly waiting for its delivery. Our primary reason for purchasing it is to use it for my Dad. He had tracheal adenocarcinoma, and had it surgically removed, his bladder, prostate urethra, and now has a urostomy. About a year after this a CT scan showed some metastatic tumours growing in his lungs. With medication we have been able to slow the growth of these down, and some are no longer visible. I’ve read through your manual and all the different frequencies relating to cancer, and I’m just unsure what one to use with him.
I have looked at a few:
“Cancer Comprehensive RDPV3 Group 6”
“Cancer Comprehensive (Alternative Set)”
“Cancer General <Run> Program”,
” Cancer General <SWEEP> Set”,
“Cancer Metastasis (Organ)”,
“Cancer Metastasis (Alternative Set)”.
We anticipate him using it every night in bed for 6-8 hours. Is there one set of frequencies you would suggest? Or even a few to use on alternate nights. Which would be the best. Any advice would be most appreciated.
Kind regards, PK
Answer:
We recommend focusing on the two core sets you mentioned:
#1: “Cancer Comprehensive RDPV3 Group 6”
#2: “Cancer Metastasis (Organ)”
These two sets are perfectly suited for your Fathers situation and can be used in the alternating schedule you described. Using “Cancer Comprehensive Rife Digital Professional V3 (RDPV3), Group 6” at night and “Cancer Metastasis (Organ)” Group 7 during the day is a very comprehensive and strategic approach. This protocol ensures a continuous and multi-faceted support system, targeting comprehensive cancer processes alongside the specific metastatic activity in the lungs.
For your reference, the other mentioned cancer treatment programs are fantastic for broader, general support, however the two sets “Cancer Comprehensive RDPV3 Group 6 and Group 7: Cancer Metastasis (Organ)” offer a more targeted strategy for your Fathers specific condition.
Finally, in your research, you may also wish to investigate the potential supportive role of Fenbendazole therapy. The Oncology Support Network provides a detailed discussion on this topic in their video, “How Quickly Does Fenbendazole Work For Cancer?” which you can find at this link:
https://www.youtube.com/watch?v=JIed99p8RzQ. Fenbendazole may offer another valuable avenue to explore for your Dad’s comprehensive care plan. It is good to use a “multi therapy” approach to achieve remission.
For a condition as complex as cancer, a multi-modal therapeutic approach is widely considered a cornerstone of modern oncology, as it aims to target the disease through multiple, complementary mechanisms to improve the likelihood of achieving remission. Within this framework, the investigation of repurposed pharmaceutical agents like Fenbendazole has garnered significant interest from the patient and research communities.
The proposed mechanisms of action, derived from in vitro (lab-based) and in vivo (animal-based) studies, indicate that Fenbendazole may function in a manner similar to certain conventional chemotherapeutics. Key hypothesized mechanisms include:
Microtubule Disruption: Fenbendazole belongs to the benzimidazole class of drugs, which are known to inhibit the formation of microtubules—critical structural components of cells. By disrupting these structures, it can impair cancer cell division (mitosis) and induce apoptosis (programmed cell death), a mechanism analogous to that of established taxane chemotherapy drugs.
Metabolic Interference: Research, including studies published in journals such as Scientific Reports, has suggested that Fenbendazole interferes with glucose uptake by cancer cells. Many cancers are highly reliant on glycolysis for energy (the Warburg effect), and disrupting this energy pathway can selectively starve tumor cells.
Reactivation of the p53 Tumor Suppressor Pathway: Some evidence indicates that Fenbendazole helps to stabilize and reactivate the p53 protein, a crucial tumor suppressor that is often deactivated in cancer cells, thereby restoring one of the body’s natural defenses against uncontrolled cell growth.
Therefore, the exploration of Fenbendazole as an adjunctive component to the Rife Digital comprehensive care plan represents a rational consideration of these potential biological synergies.
